NO20024321L - Fremgangsmate for fremstilling av krystallinsk form I av kabergolin - Google Patents

Fremgangsmate for fremstilling av krystallinsk form I av kabergolin

Info

Publication number
NO20024321L
NO20024321L NO20024321A NO20024321A NO20024321L NO 20024321 L NO20024321 L NO 20024321L NO 20024321 A NO20024321 A NO 20024321A NO 20024321 A NO20024321 A NO 20024321A NO 20024321 L NO20024321 L NO 20024321L
Authority
NO
Norway
Prior art keywords
cabergoline
crystalline form
preparation
toluene
recovery
Prior art date
Application number
NO20024321A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024321D0 (no
Inventor
Attilio Tomasi
Mario Ungari
Giafranco Pallanza
Stefania Magenes
Giuliano Ramella
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024321(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20024321D0 publication Critical patent/NO20024321D0/no
Publication of NO20024321L publication Critical patent/NO20024321L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20024321A 2000-03-24 2002-09-10 Fremgangsmate for fremstilling av krystallinsk form I av kabergolin NO20024321L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0007308.0A GB0007308D0 (en) 2000-03-24 2000-03-24 Process for preparing crystalline form | of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en) 2000-03-24 2001-03-19 Process for preparing crystalline form i of cabergoline

Publications (2)

Publication Number Publication Date
NO20024321D0 NO20024321D0 (no) 2002-09-10
NO20024321L true NO20024321L (no) 2002-09-10

Family

ID=9888433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024321A NO20024321L (no) 2000-03-24 2002-09-10 Fremgangsmate for fremstilling av krystallinsk form I av kabergolin

Country Status (31)

Country Link
US (2) US6727363B2 (enExample)
EP (1) EP1272489B1 (enExample)
JP (1) JP4184666B2 (enExample)
KR (1) KR100827558B1 (enExample)
CN (1) CN1188412C (enExample)
AR (1) AR032449A1 (enExample)
AT (1) ATE250601T1 (enExample)
AU (2) AU780747B2 (enExample)
BR (1) BR0109507A (enExample)
CA (1) CA2402836A1 (enExample)
CZ (1) CZ20023176A3 (enExample)
DE (1) DE60100858T2 (enExample)
DK (1) DK1272489T3 (enExample)
EA (1) EA005928B1 (enExample)
EE (1) EE05088B1 (enExample)
ES (1) ES2208602T3 (enExample)
GB (1) GB0007308D0 (enExample)
HK (1) HK1052348B (enExample)
HU (1) HUP0300591A3 (enExample)
IL (2) IL150985A0 (enExample)
MX (1) MXPA02009283A (enExample)
MY (1) MY134189A (enExample)
NO (1) NO20024321L (enExample)
NZ (1) NZ521316A (enExample)
PE (1) PE20011140A1 (enExample)
PL (1) PL358253A1 (enExample)
PT (1) PT1272489E (enExample)
SI (1) SI1272489T1 (enExample)
SK (1) SK13582002A3 (enExample)
WO (1) WO2001070740A1 (enExample)
ZA (1) ZA200206045B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
MXPA04008935A (es) * 2002-03-15 2004-11-26 Pharmacia Corp Procedimiento para la preparacion de la forma i cristalina de la cabergolina.
US20060281777A1 (en) * 2002-03-15 2006-12-14 Pfizer Inc. Process for preparing crystalline form I of cabergoline
IL155545A (en) 2003-04-21 2009-12-24 Finetech Pharmaceutical Ltd Solvate form of cabergoline
KR20060028761A (ko) * 2003-05-08 2006-04-03 아이박스 파마슈티컬스 에스.알.오. 다형의 카베르골린
GB0409785D0 (en) * 2004-04-30 2004-06-09 Resolution Chemicals Ltd Preparation of cabergoline
GB0505965D0 (en) 2005-03-23 2005-04-27 Resolution Chemicals Ltd Preparation of cabergoline
GB0515430D0 (en) * 2005-07-27 2005-08-31 Resolution Chemicals Ltd Preparation of cabergoline
US7339060B2 (en) 2005-03-23 2008-03-04 Resolution Chemicals, Ltd. Preparation of cabergoline
EP1925616A1 (en) * 2006-10-26 2008-05-28 LEK Pharmaceuticals D.D. Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en) 2007-01-31 2008-08-06 LEK Pharmaceuticals D.D. New crystal form of cabergoline
EP2185169A2 (en) * 2007-08-29 2010-05-19 Max Zeller Söhne AG Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) * 2021-04-16 2024-04-03 Thermo King LLC Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019322A1 (de) 1980-05-21 1981-12-03 Merck Patent Gmbh, 6100 Darmstadt Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) * 1981-08-11 1985-04-11 Erba Farmitalia Ergoline derivatives
GB9205439D0 (en) * 1992-03-12 1992-04-22 Erba Carlo Spa Process for the synthesis of ergoline derivatives
AU680539B2 (en) 1993-08-18 1997-07-31 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
WO1999036095A1 (en) 1998-01-13 1999-07-22 Astrazeneca Uk Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
EP1066038B1 (en) 1998-03-27 2005-12-21 Pharmacia & Upjohn Company LLC Use of cabergoline in the treatment of restless legs syndrome
GB0007307D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form || of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
GB0007309D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline

Also Published As

Publication number Publication date
CZ20023176A3 (cs) 2003-02-12
CN1419554A (zh) 2003-05-21
NO20024321D0 (no) 2002-09-10
EP1272489B1 (en) 2003-09-24
ES2208602T3 (es) 2004-06-16
AU2005203071B2 (en) 2007-10-18
DK1272489T3 (da) 2003-12-15
WO2001070740A1 (en) 2001-09-27
KR20020081587A (ko) 2002-10-28
AU780747B2 (en) 2005-04-14
EA200201016A1 (ru) 2003-02-27
GB0007308D0 (en) 2000-05-17
JP2003528100A (ja) 2003-09-24
DE60100858D1 (de) 2003-10-30
CN1188412C (zh) 2005-02-09
ATE250601T1 (de) 2003-10-15
NZ521316A (en) 2004-05-28
PE20011140A1 (es) 2001-11-01
HUP0300591A2 (hu) 2003-07-28
US6727363B2 (en) 2004-04-27
IL150985A0 (en) 2003-02-12
BR0109507A (pt) 2002-12-10
CA2402836A1 (en) 2001-09-27
PT1272489E (pt) 2004-02-27
MY134189A (en) 2007-11-30
US20030149067A1 (en) 2003-08-07
HK1052348B (zh) 2005-09-16
EP1272489A1 (en) 2003-01-08
US20040092744A1 (en) 2004-05-13
JP4184666B2 (ja) 2008-11-19
HUP0300591A3 (en) 2009-01-28
DE60100858T2 (de) 2004-07-29
EE200200545A (et) 2004-04-15
EE05088B1 (et) 2008-10-15
SI1272489T1 (en) 2004-02-29
AU2005203071A1 (en) 2005-08-11
HK1052348A1 (en) 2003-09-11
SK13582002A3 (sk) 2003-04-01
MXPA02009283A (es) 2003-03-12
EA005928B1 (ru) 2005-08-25
AR032449A1 (es) 2003-11-12
US6953854B2 (en) 2005-10-11
KR100827558B1 (ko) 2008-05-07
AU6211001A (en) 2001-10-03
ZA200206045B (en) 2003-07-29
PL358253A1 (en) 2004-08-09
IL150985A (en) 2007-03-08

Similar Documents

Publication Publication Date Title
NO20024321L (no) Fremgangsmate for fremstilling av krystallinsk form I av kabergolin
NO20083446L (no) Fenyl-piperazinderivater som serotonin-reopptaksinhibitorer
MXPA02012795A (es) Carvedilol.
NO992825L (no) Fremgangsmåter for fremstilling av 9,11-epoksysteroider og derved brukbare mellomprodukter
ZA200202568B (en) Process for the synthesis of silicoaluminophosphate molecular sieves.
NO20085417L (no) Krystallinske former av 11beta-(4-acetylfenyl)-20,20,21,21,21-pentafluor-17-hydroksy-19-nor-17alfa-pregna-4,9-dien-3-on
EP0029265B1 (en) A method for preparing azetidine derivatives, male sterility in plants producing compositions containing them, their use in sterilizing male parts in plants, a method of producing f1 hybrid seed and certain novel azetidine derivatives
IL163985A0 (en) Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulation
UA72895C2 (uk) Нова кристалічна модифікація n торасеміду
DK1133511T3 (da) Hidtil ukendte mellemprodukter, fremgangsmåde til fremstilling af makrolidantibiotikum derudfra
EE200100060A (et) (1H)benso[c]kinolisiin-3-ooni derivaatide sünteesi meetod
ID26346A (id) PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT
AU5936901A (en) Process for preparing azacycloalkanoylaminothiazoles
WO2004069774A3 (en) Synthesis of 13c-labelled estrogen analogues
NO20050720L (no) Krystallformer av olanzapin og fremgangsmate for deres fremstilling
MXPA04008935A (es) Procedimiento para la preparacion de la forma i cristalina de la cabergolina.
EA200201003A1 (ru) Аморфная модификация торасемида
NO940090L (no) Blanding for makrodefekt-fri sement, samt fremgangsmåte for fremstilling av denne
EP1431278A4 (en) METHOD FOR PRODUCING (2-NITROPHENYL) ACETONITRILE DERIVATIVES AND ASSOCIATED INTERMEDIATES
DE69935250D1 (de) Oleandomycin-derivate
FR2854402A1 (fr) Nouveau procede et intermediaires de preparation de composes 19-nor-steroides
DE60014096D1 (de) Durch 11-beta-aryl-17,17-spirothiolan substituierte steroide
WO2001066062A3 (en) Process for preparing pure crystalline lorazepam
MEP56208A (en) Caloporoside derivatives, methods for the production thereof and their use
ATE299147T1 (de) Verfahren zur herstellung von 3-amino-1,5- benzodiazepinderivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application